查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600464

气喘治疗市场：依产品、药物类别、给药途径 - 2025-2030 年全球预测

Asthma Therapeutics Market by Product (Inhalers, Nebulizers), Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapy), Route of administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年气喘治疗市值为247亿美元，预计2024年将达272.6亿美元，复合年增长率为10.63%，预计到2030年将达到501亿美元。

气喘治疗市场包括一系列旨在缓解和控制气喘症状的产品和治疗方法，气喘是一种影响全球数百万人的慢性呼吸道疾病。由于都市化、污染和遗传易感性等因素，气喘盛行率不断上升，凸显了对有效气喘治疗的需求。这些治疗方法包括从立即缓解药物（如支气管扩张剂）到长期控制药物（如吸入性皮质类固醇和生技药品），并根据气喘的严重程度进行调整。最终用途范围主要包括患者接受治疗或自我管理的医院、诊所和居家医疗机构。

主要市场统计
基准年[2023] 247亿美元
预测年份 [2024] 272.6亿美元
预测年份 [2030] 501亿美元
复合年增长率（%） 10.63%

该市场的关键成长要素包括环境过敏原的增加、药物输送系统（例如智慧吸入器）的技术进步以及更容易患呼吸道疾病的老年人数量的增加。新的商机在于个人化医疗，其中专注于基因组和表型分析的研究可以带来量身定制的治疗策略。不断扩大的生物製药产业也透过开发新型生技药品提供了一条利润丰厚的道路。公司应利用与高科技公司的合作伙伴关係来开发智慧监控系统，并利用远端医疗的潜力来提高患者的依从性。

然而，治疗成本高、长期使用气喘药物可能产生的副作用以及用药依从性不一致等挑战正在阻碍市场成长。此外，监管限制和新药认证的管线延误也增加了市场挑战。为了确保业务成长，公司应专注于开发负担得起的学名药，投资于创新製剂的研发，并加强教育计画以提高对气喘管理的认识。

气喘治疗市场是一个充满活力的市场，需要不断创新以适应不断变化的医疗需求。透过解决高成本并关注患者教育，公司可以显着影响患者的治疗效果并充分利用成长机会。在精准医疗的引领下，市场可望取得重大进展。

市场动态：揭示快速发展的气喘治疗市场的关键市场洞察

供需的动态交互作用正在改变气喘治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 气喘和其他呼吸道疾病的增加
    • 过敏检测和诊断技术的最新进展
    • 对单株抗体的需求不断增长
  • 市场限制因素
    • 气喘治疗设备的限制和副作用
  • 市场机会
    • 治疗联合疗法的开发
    • 气喘治疗的广泛研究与发展 (R&D) 工作
  • 市场问题
    • 偏远和农村地区接受治疗方法的情况有限

波特五力：开拓气喘治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解气喘治疗市场的外在影响

外部宏观环境因素在塑造气喘治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解气喘治疗市场的竞争格局

对气喘治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：气喘治疗市场供应商的绩效评估

FPNV定位矩阵是评估气喘治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 气喘和其他呼吸道疾病的发生率增加
      • 过敏检测和诊断技术的最新进展
      • 对单株抗体的需求不断增长
    • 抑制因素
      • 气喘治疗设备的限制和副作用
    • 机会
      • 治疗联合治疗的开发
      • 气喘治疗的广泛研究和开发工作
    • 任务
      • 偏远和农村地区的治疗供应有限
  • 市场区隔分析
    • 产品：用于气喘治疗的定量吸入器的需求增加
    • 药物类别：增加发炎药物在气喘治疗的使用
    • 给药途径：扩大吸入性气喘药物的使用以实现快速缓解
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化

第六章气喘治疗市场：副产品

  • 介绍
  • 吸入器
    • 干粉吸入器
    • 定量吸入器
    • 缓雾吸入器
  • 喷雾器

第七章气喘治疗市场：依药物类别

  • 介绍
  • 发炎（药
  • 支气管扩张剂
  • 联合治疗

第八章气喘治疗市场：依给药途径分类

  • 介绍
  • 吸入
  • 口服

第九章美洲气喘治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太气喘治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的气喘治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • GSK 斥资 14 亿美元收购 Aiolos Bio，强化呼吸产品组合
    • Teva 和 Biolojic Design 宣布签署独家授权合约，开发治疗异位性皮肤炎和气喘的抗体
    • Lupin 推出成人气喘和慢性阻塞性肺病治疗药物“Lufovec (R) 100/6”

公司名单

  • Genentech, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • Chiesi Farmaceutici SpA
  • Boston Scientific Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Medtronic PLC
  • Softhale NV by invoX Pharma Limited
  • Koninklijke Philips NV
  • Wellinks, Inc.
  • Viatris Inc.
  • Amgen Inc.
  • Sanofi SA
  • Biogen Inc.
  • AstraZeneca PLC
  • Merck & Co, Inc.
  • Parekhplast India Limited
  • GlaxoSmithKline PLC
  • Kare Medical and Analytical Devices Ltd. Co.
  • Sun Pharmaceutical Industries Limited
  • Abbott Laboratories
  • Shenzhen Aeon Technology Co., Ltd.
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd
  • Lupin Limited
  • Trudell Medical Limited
  • Cipla Limited
  • Merxin Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
Product Code: MRR-AB49FC1AB810

The Asthma Therapeutics Market was valued at USD 24.70 billion in 2023, expected to reach USD 27.26 billion in 2024, and is projected to grow at a CAGR of 10.63%, to USD 50.10 billion by 2030.

The asthma therapeutics market encompasses a wide array of products and treatments aimed at alleviating symptoms and managing asthma, a chronic respiratory condition affecting millions globally. The necessity for effective asthma therapeutics is underscored by the rising prevalence of asthma, attributable to factors such as urbanization, pollution, and genetic susceptibility. The application of these therapeutics spans from quick-relief medications, like bronchodilators, to long-term control agents, including inhaled corticosteroids and biologics, tailored to various grades of asthma severity. End-use scope primarily includes hospitals, clinics, and homecare settings, where patients either receive or self-administer treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 24.70 billion
Estimated Year [2024] USD 27.26 billion
Forecast Year [2030] USD 50.10 billion
CAGR (%) 10.63%

Key growth influencers in the market include an increase in environmental allergens, technological advancements in drug delivery systems (like smart inhalers), and an expanding geriatric population who are more prone to respiratory ailments. Emerging opportunities lie in personalized medicine, with research focusing on genomic and phenotypic profiling leading to tailored therapeutic strategies. The expanding biopharmaceutical sector also presents lucrative avenues through the development of novel biologics. Companies should leverage partnerships with tech firms to develop intelligent monitoring systems and improve patient adherence, tapping into the potential of telemedicine.

However, market growth is hindered by challenges such as high treatment costs, potential side effects of long-term asthma medication use, and inconsistent medical adherence. Furthermore, regulatory constraints and a slow pipeline for new drug approvals add to market challenges. To ensure business growth, companies should focus on developing affordable generics, invest in R&D for innovative drug formulations, and enhance educational programs to raise awareness of asthma management.

The asthma therapeutics market is dynamic, requiring continuous innovation to adapt to evolving healthcare needs. By addressing high costs and emphasizing patient education, businesses can significantly impact patient outcomes and capitalise on growth opportunities. With precision medicine leading the way, the market is poised for significant advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Asthma Therapeutics Market

The Asthma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing Incidences of Asthma and Other Respiratory Diseases
    • Recent Improvements in Allergy Detection and Diagnostic Technologies
    • Extensive Demand for Monoclonal Antibodies
  • Market Restraints
    • Limitation and Side Effects of Asthma Therapeutic Devices
  • Market Opportunities
    • Development of Combination Therapeutics for The Treatment
    • Extensive Research and Development (R&D) Efforts for Asthma Treatment
  • Market Challenges
    • Limited Therapeutics Reach in Remote & Rural Areas

Porter's Five Forces: A Strategic Tool for Navigating the Asthma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Asthma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Asthma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Asthma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Asthma Therapeutics Market

A detailed market share analysis in the Asthma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Asthma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Asthma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Asthma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Genentech, Inc., Pfizer Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Boston Scientific Corporation, Sunovion Pharmaceuticals, Inc., Medtronic PLC, Softhale NV by invoX Pharma Limited, Koninklijke Philips N.V., Wellinks, Inc., Viatris Inc., Amgen Inc., Sanofi S.A., Biogen Inc., AstraZeneca PLC, Merck & Co, Inc., Parekhplast India Limited, GlaxoSmithKline PLC, Kare Medical and Analytical Devices Ltd. Co., Sun Pharmaceutical Industries Limited, Abbott Laboratories, Shenzhen Aeon Technology Co., Ltd., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Lupin Limited, Trudell Medical Limited, Cipla Limited, Merxin Ltd., Novartis AG, and Regeneron Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Asthma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Inhalers and Nebulizers. The Inhalers is further studied across Dry Powder Inhalers, Metered-Dose Inhalers, and Soft Mist Inhalers.
  • Based on Drug Class, market is studied across Anti-Inflammatory, Bronchodilators, and Combination Therapy.
  • Based on Route of administration, market is studied across Inhaled and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidences of Asthma and Other Respiratory Diseases
      • 5.1.1.2. Recent Improvements in Allergy Detection and Diagnostic Technologies
      • 5.1.1.3. Extensive Demand for Monoclonal Antibodies
    • 5.1.2. Restraints
      • 5.1.2.1. Limitation and Side Effects of Asthma Therapeutic Devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of Combination Therapeutics for The Treatment
      • 5.1.3.2. Extensive Research and Development (R&D) Efforts for Asthma Treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Therapeutics Reach in Remote & Rural Areas
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising demand for metered dose inhalers for the treatment of asthma
    • 5.2.2. Drug Class: Growing usage of anti-Inflammatory drugs in asthma therapeutics
    • 5.2.3. Route of administration: Expanding adoption of inhaled asthma medication for fast relief
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Asthma Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Inhalers
    • 6.2.1. Dry Powder Inhalers
    • 6.2.2. Metered-Dose Inhalers
    • 6.2.3. Soft Mist Inhalers
  • 6.3. Nebulizers

7. Asthma Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Bronchodilators
  • 7.4. Combination Therapy

8. Asthma Therapeutics Market, by Route of administration

  • 8.1. Introduction
  • 8.2. Inhaled
  • 8.3. Oral

9. Americas Asthma Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Asthma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Asthma Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition
    • 12.3.2. Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
    • 12.3.3. Lupin Launches Luforbec(R) 100/6 for Adult Asthma and COPD Treatment

Companies Mentioned

  • 1. Genentech, Inc.
  • 2. Pfizer Inc.
  • 3. Takeda Pharmaceutical Company
  • 4. Teva Pharmaceutical Industries Ltd.
  • 5. Chiesi Farmaceutici S.p.A.
  • 6. Boston Scientific Corporation
  • 7. Sunovion Pharmaceuticals, Inc.
  • 8. Medtronic PLC
  • 9. Softhale NV by invoX Pharma Limited
  • 10. Koninklijke Philips N.V.
  • 11. Wellinks, Inc.
  • 12. Viatris Inc.
  • 13. Amgen Inc.
  • 14. Sanofi S.A.
  • 15. Biogen Inc.
  • 16. AstraZeneca PLC
  • 17. Merck & Co, Inc.
  • 18. Parekhplast India Limited
  • 19. GlaxoSmithKline PLC
  • 20. Kare Medical and Analytical Devices Ltd. Co.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Abbott Laboratories
  • 23. Shenzhen Aeon Technology Co., Ltd.
  • 24. Boehringer Ingelheim GmbH
  • 25. F. Hoffmann-La Roche Ltd
  • 26. Lupin Limited
  • 27. Trudell Medical Limited
  • 28. Cipla Limited
  • 29. Merxin Ltd.
  • 30. Novartis AG
  • 31. Regeneron Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. ASTHMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ASTHMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ASTHMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ASTHMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ASTHMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ASTHMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ASTHMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ASTHMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ASTHMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023